Haiying Cui1, Yao Wang2, Fei Li1, Guangyu He1, Zongmiao Jiang1, Xiaokun Gang3, Guixia Wang4. 1. Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. 2. Department of Orthopedics, The Second Hospital Jilin University, Changchun, 130021, Jilin Province, China. 3. Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. insightful@126.com. 4. Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, 130021, Jilin Province, China. gwang168@jlu.edu.cn.
Abstract
BACKGROUND: Androgen deprivation therapy (ADT) administration was recently reported and might be positively associated with dementia. However, the existing studies showed controversial results. The aim of this study was to evaluate the relationship between ADT and the risk of dementia through a meta-analysis. METHODS: Original articles published up to March 2020 were retrieved from Embase, Pubmed, the Cochrane library, and Web of Science for studies focusing on associations between ADT for prostate cancer (PCa) and incidence of dementia. A meta-analysis was conducted using a hazard ratio (HR) and 95% confidence interval (CI) as effect measures. Heterogeneity between the studies was examined using I2 statistics. Subgroup analyses, sensitivity analyses, and meta-regression were conducted, and publication bias was assessed by Egger's test. RESULTS: Thirteen studies were included in this systematic review. Eleven cohort studies involving 339,400 cases and 436,851 controls were included in the main meta-analysis. ADT administration was associated with a 21% increase in dementia risk (pooled HR = 1.21, 95% CI: 1.13-1.30, P < 0.001). Subgroup analyses based on ADT types showed that luteinizing hormone-releasing hormone agonists (HR = 1.14, P < 0.001), bilateral orchiectomy (HR = 1.42, P < 0.001), oral antiandrogens (HR = 1.35, P = 0.138), and combined androgen blockade (HR = 1.22, P = 0.097) were positively related to subsequent risk of dementia, although the differences were not statistically significant with oral antiandrogens and combined androgen blockade. CONCLUSIONS: The current study indicated that ADT administration, no matter with types of ADT, is associated with the risk of dementia in patients with PCa. Future studies are needed to determine whether ADT causes dementia or is merely associated with increased risk.
BACKGROUND:Androgen deprivation therapy (ADT) administration was recently reported and might be positively associated with dementia. However, the existing studies showed controversial results. The aim of this study was to evaluate the relationship between ADT and the risk of dementia through a meta-analysis. METHODS: Original articles published up to March 2020 were retrieved from Embase, Pubmed, the Cochrane library, and Web of Science for studies focusing on associations between ADT for prostate cancer (PCa) and incidence of dementia. A meta-analysis was conducted using a hazard ratio (HR) and 95% confidence interval (CI) as effect measures. Heterogeneity between the studies was examined using I2 statistics. Subgroup analyses, sensitivity analyses, and meta-regression were conducted, and publication bias was assessed by Egger's test. RESULTS: Thirteen studies were included in this systematic review. Eleven cohort studies involving 339,400 cases and 436,851 controls were included in the main meta-analysis. ADT administration was associated with a 21% increase in dementia risk (pooled HR = 1.21, 95% CI: 1.13-1.30, P < 0.001). Subgroup analyses based on ADT types showed that luteinizing hormone-releasing hormone agonists (HR = 1.14, P < 0.001), bilateral orchiectomy (HR = 1.42, P < 0.001), oral antiandrogens (HR = 1.35, P = 0.138), and combined androgen blockade (HR = 1.22, P = 0.097) were positively related to subsequent risk of dementia, although the differences were not statistically significant with oral antiandrogens and combined androgen blockade. CONCLUSIONS: The current study indicated that ADT administration, no matter with types of ADT, is associated with the risk of dementia in patients with PCa. Future studies are needed to determine whether ADT causes dementia or is merely associated with increased risk.
Authors: Andrew H Ford; Bu B Yeap; Leon Flicker; Graeme J Hankey; S A Paul Chubb; Jonathan Golledge; Osvaldo P Almeida Journal: Psychoneuroendocrinology Date: 2018-08-09 Impact factor: 4.905
Authors: Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Maxine Sun; Alexander P Cole; Nawar Hanna; Lorelei A Mucci; Donna L Berry; Shehzad Basaria; David K Ahern; Adam S Kibel; Toni K Choueiri; Quoc-Dien Trinh Journal: J Urol Date: 2018-02-02 Impact factor: 7.450
Authors: Bum Sik Tae; Byung Jo Jeon; Seung Hun Shin; Hoon Choi; Jae Hyun Bae; Jae Young Park Journal: Cancer Res Treat Date: 2018-07-18 Impact factor: 4.679
Authors: Chris R Cardwell; Joe M O'Sullivan; Suneil Jain; Mark T Harbinson; Michael B Cook; Blánaid M Hicks; Úna C McMenamin Journal: Epidemiology Date: 2020-05 Impact factor: 4.860
Authors: Jen-Tsan Chi; Pao-Hwa Lin; Vladimir Tolstikov; Taofik Oyekunle; Gloria C G Alvarado; Adela Ramirez-Torres; Emily Y Chen; Valerie Bussberg; Bo Chi; Bennett Greenwood; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish; Stephen J Freedland Journal: Prostate Date: 2021-05-05 Impact factor: 4.012